Home
Categories
EXPLORE
True Crime
Comedy
Society & Culture
Business
Sports
Technology
Health & Fitness
About Us
Contact Us
Copyright
© 2024 PodJoint
Podjoint Logo
US
00:00 / 00:00
Sign in

or

Don't have an account?
Sign up
Forgot password
https://is1-ssl.mzstatic.com/image/thumb/Podcasts211/v4/ab/15/a2/ab15a298-7a89-2c56-e8ee-154ffb5c4ea5/mza_15379307726488344733.jpg/600x600bb.jpg
DCAT Value Chain Insights’ Production to Prescription
DCAT
51 episodes
2 weeks ago
Which bio/pharmaceuticals, launched or approved thus far in 2025, may be potential blockbusters (defined as drugs with sales of $1 billion or more) in the mid term, and what upcoming launches or approvals and trends should be on the industry’s radar? Matthew Arnold, Principal Analyst and Content Strategist, Clarivate, provides the latest developments and insights. Support the show
Show more...
Business
Science
RSS
All content for DCAT Value Chain Insights’ Production to Prescription is the property of DCAT and is served directly from their servers with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Which bio/pharmaceuticals, launched or approved thus far in 2025, may be potential blockbusters (defined as drugs with sales of $1 billion or more) in the mid term, and what upcoming launches or approvals and trends should be on the industry’s radar? Matthew Arnold, Principal Analyst and Content Strategist, Clarivate, provides the latest developments and insights. Support the show
Show more...
Business
Science
https://is1-ssl.mzstatic.com/image/thumb/Podcasts211/v4/ab/15/a2/ab15a298-7a89-2c56-e8ee-154ffb5c4ea5/mza_15379307726488344733.jpg/600x600bb.jpg
Rising Energy Costs and API Supply
DCAT Value Chain Insights’ Production to Prescription
17 minutes
4 years ago
Rising Energy Costs and API Supply
Escalating energy prices are impacting global manufacturing and supply chains. In the EU, leaders are proposing measures to alleviate pricing pressures. What’s the plan? Key topics: (see Chapter Markers) Economic recovery brings pricing pressuresRising energy costs and the bio/pharma manufacturing value chain Rising energy costs: call for action in the EU Ripple effect throughout industrial supply chainsActions proposed by the European CommissionProposals for energy-price reliefSp...
DCAT Value Chain Insights’ Production to Prescription
Which bio/pharmaceuticals, launched or approved thus far in 2025, may be potential blockbusters (defined as drugs with sales of $1 billion or more) in the mid term, and what upcoming launches or approvals and trends should be on the industry’s radar? Matthew Arnold, Principal Analyst and Content Strategist, Clarivate, provides the latest developments and insights. Support the show